NewsBenzinga소파이 테크놀로지스, 2026회계연도 조정 주당순이익 가이던스 0.60달러에서 0.90달러로 상향 조정 (시장 예상 0.59달러) 및 매출 가이던스 47억 5천만~48억 5천만 달러에서 50억 4천만 달러로 상향 조정 (시장 예상 48억 7,400만 달러) 소파이 테크놀로지스, 2026회계연도 조정 주당순이익 가이던스 0.60달러에서 0.90달러로 상향 조정 (시장 예상 0.59달러) 및 매출 가이던스 47억 5천만~48억 5천만 달러에서 50억 4천만 달러로 상향 조정 (시장 예상 48억 7,400만 달러) Benzinga 2026.10.27 11:02 (GMT+0) Open on Benzinga Other news Global-E Online Stock Is Falling Wednesday: What's Going On? Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease HC Wainwright & Co. Maintains Buy on LifeMD, Lowers Price Target to $6 Stifel Maintains Buy on Ecolab, Raises Price Target to $356 Stifel Upgrades Tandem Diabetes Care to Buy, Raises Price Target to $26 Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients
Grifols Presents New Real-World Evidence Data From AMBAR Program, Contributing To Ongoing Research Evaluating Use Of TPE With Albumin Replacement In Patients With Alzheimer’s Disease
Immuneering Presents Preclinical Data Demonstrating Potential Of Atebimetinib; Phase 2 Results Include Long Survival And Outstanding Tolerability Profile In First-Line Pancreatic Cancer Patients